Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Vladislav Berdunov, Steve Millen, Andrew Paramore, Jane Griffin, Sarah Reynia, Nina Fryer, Rebecca Brown & Louise Longworth. (2022) Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer. ClinicoEconomics and Outcomes Research 14, pages 448-633.
Read now
Read now
Articles from other publishers (37)
Felix E. de Jongh, Reva Efe, Kirsten H. Herrmann & Jelle A. Spoorendonk. (2022) Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. International Journal of Breast Cancer 2022, pages 1-12.
Crossref
Crossref
Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi & Arndt Hartmann. (2022) Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting. International Journal of Molecular Sciences 23:15, pages 8716.
Crossref
Crossref
Rino S. Seedor, Marlana Orloff & Takami Sato. (2021) Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers 13:21, pages 5503.
Crossref
Crossref
Bradley M. Turner, Hani Katerji, Huina Zhang & David G. Hicks. (2021) Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. Human Pathology Reports 26, pages 300574.
Crossref
Crossref
Paolo Giorgi Rossi, Annette Lebeau, Carlos Canelo-Aybar, Zuleika Saz-Parkinson, Cecily Quinn, Miranda Langendam, Helen Mcgarrigle, Sue Warman, David Rigau, Pablo Alonso-Coello, Mireille Broeders, Axel Graewingholt, Margarita Posso, Stephen Duffy, Holger J. Schünemann, Mariangela Autelitano, Bettina Borisch, Xavier Castells, Edoardo Colzani, Jan Daneš, Patricia Fitzpatrick, Livia Giordano, Solveig Hofvind, Lydia Ioannidou-Mouzaka, Susan Knox, Lennarth Nystrom, Elena Parmelli, Elsa Perez, Alberto Torresin, Ruben Van Engen, Cary Van Landsveld-Verhoeven & Ken Young. (2021) Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. British Journal of Cancer 124:9, pages 1503-1512.
Crossref
Crossref
Yahiya Y. Syed. (2020) Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer. Molecular Diagnosis & Therapy 24:5, pages 621-632.
Crossref
Crossref
Shahid Ahmed, Sukanya Pati, Duc Le, Kamal Haider & Nayyar Iqbal. (2020) The prognostic and predictive role of 21‐gene recurrence scores in hormone receptor‐positive early‐stage breast cancer. Journal of Surgical Oncology 122:2, pages 144-154.
Crossref
Crossref
Carlo Boeri, Corrado Chiappa, Federica Galli, Valentina De Berardinis, Laura Bardelli, Giulio Carcano & Francesca Rovera. (2020) Machine Learning techniques in breast cancer prognosis prediction: A primary evaluation. Cancer Medicine 9:9, pages 3234-3243.
Crossref
Crossref
Oliver Ibarrondo, Isabel Álvarez-López, Frederick Freundlich, Arantzazu Arrospide, Elena Galve-Calvo, María Gutiérrez-Toribio, Arrate Plazaola & Javier Mar. (2020) Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. Gaceta Sanitaria 34:1, pages 61-68.
Crossref
Crossref
Sae Byul Lee, Junetae Kim, Guiyun Sohn, Jisun Kim, Il Yong Chung, Hee Jeong Kim, Beom Seok Ko, Byung Ho Son, Sei-Hyun Ahn, Jong Won Lee & Kyung Hae Jung. (2019) A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer. Cancer Research and Treatment 51:3, pages 1073-1085.
Crossref
Crossref
Sue Harnan, Paul Tappenden, Katy Cooper, John Stevens, Alice Bessey, Rachid Rafia, Sue Ward, Ruth Wong, Robert C Stein & Janet Brown. (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment 23:30, pages 1-328.
Crossref
Crossref
Shi-Yi WangWeixiong DangIlana RichmanSarah S. MougalianSuzanne B. EvansCary P. Gross. (2018) Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal of Clinical Oncology 36:16, pages 1619-1627.
Crossref
Crossref
Young ChandlerClyde B. SchechterJinani JayasekeraAimee NearSuzanne C. O’NeillClaudine IsaacsCharles E. PhelpsG. Thomas RayTracy A. LieuScott RamseyJeanne S. Mandelblatt. (2018) Cost Effectiveness of Gene Expression Profile Testing in Community Practice. Journal of Clinical Oncology 36:6, pages 554-562.
Crossref
Crossref
E.J. Blok, E. Bastiaannet, W.B. van den Hout, G.J. Liefers, V.T.H.B.M. Smit, J.R. Kroep & C.J.H. van de Velde. (2018) Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treatment Reviews 62, pages 74-90.
Crossref
Crossref
Christos Markopoulos. 2018. Breast Cancer Management for Surgeons. Breast Cancer Management for Surgeons
89
101
.
Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel, David B. Geffen, Bella Nisenbaum, Tamar Peretz, Lior Soussan-Gutman, Avital Bareket-Samish, Kevin Isaacs, Ora Rosengarten, Georgeta Fried, Debbie McCullough, Christer Svedman, Steven Shak, Nicky Liebermann & Noa Ben-Baruch. (2017) Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. npj Breast Cancer 3:1.
Crossref
Crossref
Jessica G. Cockburn, Robin M. Hallett, Amy E. Gillgrass, Kay N. Dias, T. Whelan, M. N. Levine, John A. Hassell & Anita Bane. (2016) The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures. BMC Cancer 16:1.
Crossref
Crossref
Virginie Nerich, Sopany Saing, Eva Maria Gamper, Georg Kemmler, Franck Daval, Xavier Pivot & Bernhard Holzner. (2016) Cost–utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Research and Treatment 159:3, pages 407-424.
Crossref
Crossref
Sophie Marguet, Chafika Mazouni, Bram L.T. Ramaekers, Ariane Dunant, Ronald Kates, Volker R. Jacobs, Manuela A. Joore, Nadia Harbeck & Julia Bonastre. (2016) European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. European Journal of Cancer 63, pages 168-179.
Crossref
Crossref
Kelly K. Curtis, William W. Wong & Helen J. Ross. (2016) Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. Critical Reviews in Oncology/Hematology 103, pages 86-98.
Crossref
Crossref
Kristen Meldi Plasseraud, Robert W. Cook, Tony Tsai, Yevgeniy Shildkrot, Brooke Middlebrook, Derek Maetzold, Jeff Wilkinson, John Stone, Clare Johnson, Kristen Oelschlager & Thomas M. Aaberg. (2016) Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study. Journal of Oncology 2016, pages 1-9.
Crossref
Crossref
Joseph GligorovXavier B. PivotWilliam JacotHervé L. NamanDominique SpaethJean-Louis MissetRémy LargillierJean-Loup SautiereAnne de RoquancourtChristophe PomelPhilippe RouanetRoman Rouzier & Frederique M. Penault-Llorca. (2015) Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. The Oncologist 20:8, pages 873-879.
Crossref
Crossref
Federico Augustovski, Natalie Soto, Joaquín Caporale, Lucas Gonzalez, Luz Gibbons & Agustín Ciapponi. (2015) Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis. Breast Cancer Research and Treatment 152:3, pages 611-625.
Crossref
Crossref
Bradley M Turner, Kristin A Skinner, Ping Tang, Mary C Jackson, Nyrie Soukiazian, Michelle Shayne, Alissa Huston, Marilyn Ling & David G Hicks. (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Modern Pathology 28:7, pages 921-931.
Crossref
Crossref
Gyöngyi Munkácsy, Marcell A. Szász & Otilia Menyhárt. (2015) Gene expression-based prognostic and predictive tools in breast cancer. Breast Cancer 22:3, pages 245-252.
Crossref
Crossref
Jennifer Mason Lobo, Adam P. Dicker, Christine Buerki, Elai Daviconi, R. Jeffrey Karnes, Robert B. Jenkins, Nirav Patel, Robert B. Den & Timothy N. Showalter. (2015) Evaluating the Clinical Impact of a Genomic Classifier in Prostate Cancer Using Individualized Decision Analysis. PLOS ONE 10:4, pages e0116866.
Crossref
Crossref
Patricia R. Blank, Martin Filipits, Peter Dubsky, Florian Gutzwiller, Michael P. Lux, Jan C. Brase, Karsten E. Weber, Margaretha Rudas, Richard Greil, Sibylle Loibl, Thomas D. Szucs, Ralf Kronenwett, Matthias Schwenkglenks & Michael Gnant. (2014) Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. PharmacoEconomics 33:2, pages 179-190.
Crossref
Crossref
Pamela N. Munster. 2015. Breast Disease. Breast Disease
321
334
.
Laura Zanotti, Alberto Bottini, Camillo Rossi, Daniele Generali & Maria Rosa Cappelletti. (2014) Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. Tumor Biology 35:9, pages 8461-8470.
Crossref
Crossref
Nadia Harbeck, Karl Sotlar, Rachel Wuerstlein & Sophie Doisneau-Sixou. (2014) Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow. Cancer Treatment Reviews 40:3, pages 434-444.
Crossref
Crossref
M. Gnant, M. Filipits, R. Greil, H. Stoeger, M. Rudas, Z. Bago-Horvath, B. Mlineritsch, W. Kwasny, M. Knauer, C. Singer, R. Jakesz, P. Dubsky, F. Fitzal, R. Bartsch, G. Steger, M. Balic, S. Ressler, J.W. Cowens, J. Storhoff, S. Ferree, C. Schaper, S. Liu, C. Fesl & T.O. Nielsen. (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Annals of Oncology 25:2, pages 339-345.
Crossref
Crossref
F. André, S. Delaloge, J. -M. Guinebretière, T. Petit, J. -Y. Pierga, D. Zarca & K. Zarca. (2013) Prolifération des cancers du sein et biomarqueurs décisionnels en pratique RPC (RPC 2013). Oncologie 15:12, pages 594-604.
Crossref
Crossref
A. Goldhirsch, E.P. Winer, A.S. Coates, R.D. Gelber, M. Piccart-Gebhart, B. Thürlimann, H.-J. Senn, Kathy S. Albain, Fabrice André, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel-Morales, Harold Burstein, Fatima Cardoso, Monica Castiglione-Gertsch, Alan S. Coates, Marco Colleoni, Alberto Costa, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John F. Forbes, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela Goodwin, Paul E. Goss, Jay R. Harris, Daniel F. Hayes, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Sibylle Loibl, Monica Morrow, Moise Namer, C. Kent Osborne, Ann H. Partridge, Frédérique Penault-Llorca, Charles M. Perou, Martine J. Piccart-Gebhart, Kathleen I. Pritchard, Emiel J.T. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Zhi-Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Michael Untch, Giuseppe Viale, Toru Watanabe, Nicholas Wilcken, Eric P. Winer & William C. Wood. (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology 24:9, pages 2206-2223.
Crossref
Crossref
Richard H BoerCaroline BakerDavid SpeakmanCalvin Y ChaoCarl YoshizawaG Bruce Mann. (2013) The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Medical Journal of Australia 199:3, pages 205-208.
Crossref
Crossref
Berit Maria Müller, Elke Keil, Annika Lehmann, Klaus-Jürgen Winzer, Christiane Richter-Ehrenstein, Judith Prinzler, Nikola Bangemann, Angela Reles, Sylvia Stadie, Winfried Schoenegg, Jan Eucker, Marcus Schmidt, Frank Lippek, Korinna Jöhrens, Stefan Pahl, Bruno Valentin Sinn, Jan Budczies, Manfred Dietel & Carsten Denkert. (2013) The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. PLoS ONE 8:6, pages e68252.
Crossref
Crossref
S Holt, G Bertelli, I Humphreys, W Valentine, S Durrani, D Pudney, M Rolles, M Moe, S Khawaja, Y Sharaiha, E Brinkworth, S Whelan, S Jones, H Bennett & C J Phillips. (2013) A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. British Journal of Cancer 108:11, pages 2250-2258.
Crossref
Crossref
N. Harbeck & R. Wuerstlein. (2013) MammakarzinomBreast cancer. Der Internist 54:2, pages 194-200.
Crossref
Crossref